rolipram

Summary

Summary: A phosphodiesterase inhibitor with antidepressant properties.

Top Publications

  1. pmc Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment
    Bing Gong
    The Center for Dementia Research, Nathan Kline Institute for Psychiatric Research, Orangeburg, New York, USA
    J Clin Invest 114:1624-34. 2004
  2. ncbi Inhibitor binding to type 4 phosphodiesterase (PDE4) assessed using [3H]piclamilast and [3H]rolipram
    Yu Zhao
    Department of Pharmacology, University of Tennessee Health Science Center, 874 Union Avenue, Memphis, TN 38163, USA
    J Pharmacol Exp Ther 305:565-72. 2003
  3. pmc Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis
    Fiona E McCann
    The Kennedy Institute of Rheumatology, Imperial College London, 65 Aspenlea Road, London, W6 8LH, UK
    Arthritis Res Ther 12:R107. 2010
  4. ncbi Inhibitory effects of quercetin derivatives on phosphodiesterase isozymes and high-affinity [(3) H]-rolipram binding in guinea pig tissues
    Agnes L F Chan
    Pharmacy Department, Chi Mei Medical Center, 901 Chung Hwa Road, Tainan, 710, Taiwan
    Invest New Drugs 26:417-24. 2008
  5. ncbi PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway
    A Robichaud
    Department of Pharmacology, Merck Frosst Centre for Therapeutic Research, PO Box 1005, Pointe Claire, Dorval, Quebec, Canada H9R 4P8
    Neuropharmacology 40:262-9. 2001
  6. pmc Downregulation of brain phosphodiesterase type IV measured with 11C-(R)-rolipram positron emission tomography in major depressive disorder
    Masahiro Fujita
    Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20892 1026, USA
    Biol Psychiatry 72:548-54. 2012
  7. pmc Effects of rolipram on adult rat oligodendrocytes and functional recovery after contusive cervical spinal cord injury
    E Beaumont
    Kentucky Spinal Cord Injury Research Center, School of Medicine, University of Louisville, Louisville, KY 40292, USA
    Neuroscience 163:985-90. 2009
  8. pmc Kinetic analysis in human brain of [11C](R)-rolipram, a positron emission tomographic radioligand to image phosphodiesterase 4: a retest study and use of an image-derived input function
    Paolo Zanotti-Fregonara
    Molecular Imaging Branch, National Institute of Mental Health, Bethesda, Maryland 20892 2035, USA
    Neuroimage 54:1903-9. 2011
  9. ncbi Quantification of brain phosphodiesterase 4 in rat with (R)-[11C]Rolipram-PET
    Masahiro Fujita
    Molecular Imaging Branch, National Institute of Mental Health, Building 1, Room B3 10, 1 Center Drive, MSC 0135, Bethesda, MD 20892 0135, USA
    Neuroimage 26:1201-10. 2005
  10. ncbi Correlation between emetic effect of phosphodiesterase 4 inhibitors and their occupation of the high-affinity rolipram binding site in Suncus murinus brain
    Ryo Hirose
    Pharmaceutical Research Center, Kyowa Hakko Kogyo Co, Ltd, 1188 Shimotogari, Nagaizumi, Shizuoka, 411 8731, Japan
    Eur J Pharmacol 573:93-9. 2007

Detail Information

Publications260 found, 100 shown here

  1. pmc Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment
    Bing Gong
    The Center for Dementia Research, Nathan Kline Institute for Psychiatric Research, Orangeburg, New York, USA
    J Clin Invest 114:1624-34. 2004
    ..Here we demonstrate that brief treatment with the phosphodiesterase 4 inhibitor rolipram ameliorates deficits in both long-term potentiation (LTP) and contextual learning in the double-transgenic mice...
  2. ncbi Inhibitor binding to type 4 phosphodiesterase (PDE4) assessed using [3H]piclamilast and [3H]rolipram
    Yu Zhao
    Department of Pharmacology, University of Tennessee Health Science Center, 874 Union Avenue, Memphis, TN 38163, USA
    J Pharmacol Exp Ther 305:565-72. 2003
    Piclamilast is a type 4 phosphodiesterase (PDE4) inhibitor with equal affinity for the high-affinity rolipram binding site (HARBS) and low-affinity rolipram binding site (LARBS)...
  3. pmc Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis
    Fiona E McCann
    The Kennedy Institute of Rheumatology, Imperial College London, 65 Aspenlea Road, London, W6 8LH, UK
    Arthritis Res Ther 12:R107. 2010
    ..We assessed the anti-inflammatory effects of a novel PDE4 inhibitor, apremilast, in human synovial cells from rheumatoid arthritis (RA) patients, as well as two murine models of arthritis...
  4. ncbi Inhibitory effects of quercetin derivatives on phosphodiesterase isozymes and high-affinity [(3) H]-rolipram binding in guinea pig tissues
    Agnes L F Chan
    Pharmacy Department, Chi Mei Medical Center, 901 Chung Hwa Road, Tainan, 710, Taiwan
    Invest New Drugs 26:417-24. 2008
    b>Rolipram has high (PDE4(H)) and low (PDE4(L)) affinities for phosphodiesterase (PDE)-4, respectively...
  5. ncbi PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway
    A Robichaud
    Department of Pharmacology, Merck Frosst Centre for Therapeutic Research, PO Box 1005, Pointe Claire, Dorval, Quebec, Canada H9R 4P8
    Neuropharmacology 40:262-9. 2001
    ..e. 6-(4-pyridylmethyl)-8-(3-nitrophenyl)quinoline, CT-2450 and R-rolipram. It was postulated that PDE4 inhibitors trigger emesis by mimicking the pharmacological actions of alpha(2)-..
  6. pmc Downregulation of brain phosphodiesterase type IV measured with 11C-(R)-rolipram positron emission tomography in major depressive disorder
    Masahiro Fujita
    Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20892 1026, USA
    Biol Psychiatry 72:548-54. 2012
    ..This study sought to quantify the binding of 11C-(R)-rolipram, a PDE4 inhibitor, as an indirect measure of this enzyme's activity in the brain of individuals with major ..
  7. pmc Effects of rolipram on adult rat oligodendrocytes and functional recovery after contusive cervical spinal cord injury
    E Beaumont
    Kentucky Spinal Cord Injury Research Center, School of Medicine, University of Louisville, Louisville, KY 40292, USA
    Neuroscience 163:985-90. 2009
    ..4 (PDE4) subtypes and that their death was attenuated up to 3 days after contusive cervical SCI when rolipram, a specific inhibitor of PDE4, was administered...
  8. pmc Kinetic analysis in human brain of [11C](R)-rolipram, a positron emission tomographic radioligand to image phosphodiesterase 4: a retest study and use of an image-derived input function
    Paolo Zanotti-Fregonara
    Molecular Imaging Branch, National Institute of Mental Health, Bethesda, Maryland 20892 2035, USA
    Neuroimage 54:1903-9. 2011
    11)C](R)-rolipram provides a measure of the density of phosphodiesterase 4 (PDE4) in brain, an enzyme that metabolizes cAMP...
  9. ncbi Quantification of brain phosphodiesterase 4 in rat with (R)-[11C]Rolipram-PET
    Masahiro Fujita
    Molecular Imaging Branch, National Institute of Mental Health, Building 1, Room B3 10, 1 Center Drive, MSC 0135, Bethesda, MD 20892 0135, USA
    Neuroimage 26:1201-10. 2005
    ..Phosphodiesterase 4 (PDE4) catabolizes the second messenger 3', 5'-cyclic adenosine monophosphate and may play a critical role in brain diseases. Our aim was to quantify PDE4 in rats with positron emission tomography (PET)...
  10. ncbi Correlation between emetic effect of phosphodiesterase 4 inhibitors and their occupation of the high-affinity rolipram binding site in Suncus murinus brain
    Ryo Hirose
    Pharmaceutical Research Center, Kyowa Hakko Kogyo Co, Ltd, 1188 Shimotogari, Nagaizumi, Shizuoka, 411 8731, Japan
    Eur J Pharmacol 573:93-9. 2007
    We employed an ex vivo [(3)H]rolipram binding experiment to elucidate the mechanism of emetic activity of phosphodiesterase 4 inhibitors...
  11. doi Beneficial effects of rolipram in the R6/2 mouse model of Huntington's disease
    Zena DeMarch
    Santa Lucia Foundation IRCCS Hospital at the European Center for Brain Research, Laboratory of Neuroanatomy, Rome, Italy
    Neurobiol Dis 30:375-87. 2008
    We have previously showed that rolipram, a phosphodiesterase type IV inhibitor, displays a neuroprotective effect in a rat quinolinic acid model of HD [DeMarch Z., Giampa C., Patassini S., Martorana A., Bernardi G. and Fusco F.R...
  12. pmc Modulation of the cAMP signaling pathway after traumatic brain injury
    Coleen M Atkins
    Department of Neurological Surgery, University of Miami Miller School of Medicine, Miami, FL 33101, USA
    Exp Neurol 208:145-58. 2007
    ..a phosphodiesterase (PDE) IV inhibitor would improve outcome after TBI, we treated animals intraperitoneally with rolipram (0.3 or 3.0 mg/kg) 30 min prior to TBI, and then once per day for 3 days...
  13. pmc Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity
    S J Kanes
    Department of Psychiatry and Center for Neurobiology and Behavior, University of Pennsylvania, Philadelphia, PA 19104, USA
    Neuroscience 144:239-46. 2007
    ..To test this hypothesis, we studied the effect of an acute treatment of rolipram, an inhibitor of type 4 phosphodiesterases that degrade cAMP, on acoustic startle and prepulse inhibition (PPI) ..
  14. ncbi Beneficial effects of rolipram in a quinolinic acid model of striatal excitotoxicity
    Zena DeMarch
    Laboratory of Neuroanatomy, Santa Lucia Foundation IRCCS at the European Center for Brain Research, Via del Fosso Fiorano 64, 00143 Rome, Italy
    Neurobiol Dis 25:266-73. 2007
    ..The phosphodiesterase type IV inhibitor rolipram increases CREB phosphorylation. Such drug has a protective effect in global ischaemia and embolism in rats...
  15. doi Combination of olfactory ensheathing cells with local versus systemic cAMP treatment after a cervical rubrospinal tract injury
    Frederic Bretzner
    ICORD International Collaboration on Repair Discoveries, Blusson Spinal Cord Centre, Department of Zoology, University of British Columbia, Vancouver, British Columbia, Canada
    J Neurosci Res 88:2833-46. 2010
    ..In addition, we assessed a systemic increase of cAMP using the phosphodiesterase inhibitor rolipram. OECs prevented cavity formation, attenuated astrocytic hypertrophy and the retraction of the axotomized ..
  16. ncbi Acute rolipram/thalidomide treatment improves tissue sparing and locomotion after experimental spinal cord injury
    Guido C Koopmans
    Department of Anesthesiology, Academic Hospital Maastricht, Maastricht, 6200 AZ, The Netherlands
    Exp Neurol 216:490-8. 2009
    ..In the present investigation, the ability of rolipram and thalidomide (FDA approved drugs) to reduce secondary tissue degeneration and improve motor function was ..
  17. doi PDE4 inhibitors roflumilast and rolipram augment PGE2 inhibition of TGF-{beta}1-stimulated fibroblasts
    Shinsaku Togo
    Pulmonary and Critical Care Medicine, University of Nebraska Medical Center, Omaha, NE 68198 5885, USA
    Am J Physiol Lung Cell Mol Physiol 296:L959-69. 2009
    ..The PDE4 inhibitors roflumilast and rolipram both inhibited fibroblast-mediated contraction of three-dimensional collagen gels and fibroblast chemotaxis ..
  18. pmc The PDE4 inhibitor rolipram prevents NF-kappaB binding activity and proinflammatory cytokine release in human chorionic cells
    Roxane Hervé
    Institut National de la Sante et de la Recherche Medicale, Unité 767, Paris, France
    J Immunol 181:2196-202. 2008
    ..The presence of the PDE4 inhibitor rolipram reduces the TNF-alpha production and the activation of the three NF-kappaB complexes...
  19. ncbi Rolipram attenuates MK-801-induced deficits in latent inhibition
    Jennifer A Davis
    Temple University, Department of Psychology, Philadelphia, PA 19122, USA
    Behav Neurosci 119:595-602. 2005
    ..The authors examine whether amplification of the cAMP signaling pathway by rolipram, a selective Type 4 cAMP phosphodiesterase inhibitor, reverses MK-801-induced impairments in latent inhibition...
  20. ncbi Crystal structures of the catalytic domain of phosphodiesterase 4B complexed with AMP, 8-Br-AMP, and rolipram
    Robert X Xu
    Department of Computational, Analytical and Structural Sciences, GlaxoSmithKline, 5 Moore Drive, V 180, Research Triangle Park, NC 27709, USA
    J Mol Biol 337:355-65. 2004
    ..0 A), 8-Br-AMP (2.13 A) and the potent inhibitor rolipram (2.0 A)...
  21. ncbi Chemoresistant KM12C colon cancer cells are addicted to low cyclic AMP levels in a phosphodiesterase 4-regulated compartment via effects on phosphoinositide 3-kinase
    David G McEwan
    The Beatson Institute for Cancer Research, Cancer Research UK Beatson Laboratories, Glasgow, United Kingdom
    Cancer Res 67:5248-57. 2007
    ..cyclase activator forskolin together with the specific cyclic AMP (cAMP) phosphodiesterase-4 (PDE4) inhibitor rolipram, but not the cAMP phosphodiesterase-3 (PDE3) inhibitor cilostamide, causes profound growth arrest of ..
  22. ncbi Inflammation contributes to the postponed ischemic neuronal damage following treatment with a glutamate antagonist in rats
    F Block
    Department of Neurology RWTH Aachen, Pauwelsstrasse 30, D 52057 Aachen, Germany
    Neurosci Lett 298:103-6. 2001
    ..The animals were treated either with NBQX, rolipram, doxycycline or a combination of NBQX and rolipram or doxycycline...
  23. ncbi Rolipram impairs NF-kappaB activity and MMP-9 expression in experimental autoimmune encephalomyelitis
    Antonio J Sanchez
    Neuroimmunology Unit, Universidad Autonoma de Madrid, Hospital Puerta de Hierro, San Martin de Porres 4, 28035, Madrid, Spain
    J Neuroimmunol 168:13-20. 2005
    b>Rolipram suppresses experimental autoimmune encephalomyelitis (EAE) and diminishes cell infiltration of the central nervous system (CNS)...
  24. pmc Activity-based therapies to promote forelimb use after a cervical spinal cord injury
    Haining Dai
    Department of Neuroscience, Georgetown University Medical Center, Washington, DC 20007, USA
    J Neurotrauma 26:1719-32. 2009
    ..A subset of animals received rolipram to promote neuronal plasticity...
  25. pmc Systemic administration of rolipram increases medullary and spinal cAMP and activates a latent respiratory motor pathway after high cervical spinal cord injury
    Satkunendrarajah Kajana
    Department of Anatomy and Cell Biology, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
    J Spinal Cord Med 32:175-82. 2009
    ..Hemisection results in the paralysis of the ipsilateral hemidiaphragm. Chronic administration of rolipram, a specific phosphodiesterase-IV inhibitor, promotes synaptic plasticity and restores phrenic nerve function ..
  26. doi A combination immunomodulatory treatment promotes neuroprotection and locomotor recovery after contusion SCI
    Christopher A Iannotti
    Center for Spine Health, Department of Neurological Surgery, Cleveland Clinic, Cleveland, OH 44195, USA
    Exp Neurol 230:3-15. 2011
    ..treatment using (1) selective depletion of peripheral macrophages with liposomal-encapsulated clodronate, and (2) rolipram, a type 4 phosphodiesterase (PDE4) inhibitor, to promote neuroprotection and improve locomotor recovery following ..
  27. doi Curative effects of phosphodiesterase 4 inhibitors cilomilast, roflumilast, and rolipram in dermatitis mouse model
    Daisuke Harada
    J Dermatol Sci 51:215-9. 2008
  28. ncbi Rolipram and SP600125 suppress the early increase in PTP1B expression during cerulein-induced pancreatitis in rats
    Nancy Sarmiento
    Department of Biochemistry, University of Salamanca, Salamanca, Spain
    Pancreas 39:639-45. 2010
    ....
  29. ncbi Rolipram, a phosphodiesterase type IV inhibitor, exacerbates periventricular white matter lesions in rat pups
    Ying Chao Chang
    Department of Pediatrics, Chang Gung Memorial Hospital, Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung, Taiwan
    Pediatr Res 64:234-9. 2008
    ..We examined whether rolipram, a phosphodiesterase type IV inhibitor, treatment after hypoxic-ischemia is protective against white matter ..
  30. pmc Drug-eluting microfibrous patches for the local delivery of rolipram in spinal cord repair
    Timothy L Downing
    UC Berkeley and UCSF Joint Graduate Program in Bioengineering, Berkeley San Francisco, CA, USA
    J Control Release 161:910-7. 2012
    ..Previous studies have demonstrated that rolipram, an anti-inflammatory and cyclic adenosine monophosphate preserving small molecule, improves spinal cord ..
  31. pmc Delayed Nogo receptor therapy improves recovery from spinal cord contusion
    Xingxing Wang
    Program in Cellular Neuroscience, Neurodegeneration and Repair, Yale University School of Medicine, New Haven, CT 06510, USA
    Ann Neurol 60:540-9. 2006
    ..Myelin-associated inhibitors play a role in limiting axonal growth in the adult central nervous system. Blocking these inhibitors may promote neurological recovery from spinal cord contusion...
  32. ncbi Association between inflammation and nigral neuronal damage following striatal excitotoxic lesion
    F Block
    Department of Neurology, University of Aachen, Pauwelsstr 30, D 52057 Aachen, Germany
    Brain Res 998:29-35. 2004
    ..nigra pars reticulata (SNR) following intrastriatal injection of quinolinic acid (QA) and studied the effect of rolipram, a TNF-alpha-inhibitor, on the secondary neuronal damage...
  33. doi Inhibition of cAMP degradation improves regulatory T cell-mediated suppression
    Tobias Bopp
    Institute for Immunology, Johannes Gutenberg University, Mainz, Germany
    J Immunol 182:4017-24. 2009
    ..Prevention of cAMP degradation by application of the phosphodiesterase 4 inhibitor rolipram led to strongly increased suppressive potency of nTreg cells for Th2 cells in vitro and in vivo...
  34. ncbi Airway relaxant and anti-inflammatory properties of a PDE4 inhibitor with low affinity for the high-affinity rolipram binding site
    Christian Martin
    Division of Pulmonary Pharmacology, Research Centre Borstel, Parkallee 22, 23845 Borstel, Germany
    Naunyn Schmiedebergs Arch Pharmacol 365:284-9. 2002
    ..PDE4 has two binding sites for the archetypal PDE4 inhibitor rolipram, and it has been suggested that binding to the high-affinity rolipram binding site (HARBS) is responsible for the ..
  35. doi Sub-chronic rolipram treatment leads to a persistent improvement in long-term object memory in rats
    K Rutten
    Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Universiteitssingel 50, P O Box 616, 6200 MD Maastricht, The Netherlands
    Neurobiol Learn Mem 90:569-75. 2008
    In the present study the effects of sub-chronic rolipram treatment in an object recognition task in 3-month-old male rats were investigated...
  36. ncbi Rolipram reduces excitotoxic neuronal damage
    F Block
    Department of Neurology RWTH Aachen, Germany
    Neuroreport 12:1507-11. 2001
    ..We examined the effect of rolipram, a TNF-alpha-inhibitor, on excitotoxic neuronal damage...
  37. pmc Maternal exposure to secondhand cigarette smoke primes the lung for induction of phosphodiesterase-4D5 isozyme and exacerbated Th2 responses: rolipram attenuates the airway hyperreactivity and muscarinic receptor expression but not lung inflammation and a
    Shashi P Singh
    Respiratory Immunology Division, Lovelace Respiratory Research Institute, Albuquerque, NM 87108, USA
    J Immunol 183:2115-21. 2009
    ..Interestingly, the PDE4-selective inhibitor rolipram attenuates the increase in AHR, muscarinic receptors, and PDE4D5, but fails to down-regulate lung inflammation, ..
  38. ncbi Local anti-inflammatory effect and behavioral studies on new PDE4 inhibitors
    Stefano Pieretti
    Department of Drug Research and Evaluation, Italian National Institute of Health, Rome, Italy
    Life Sci 79:791-800. 2006
    ..CC12) reduced the paw edema induced by zymosan in mice as rolipram (the PDE4 inhibitor prototype with anti-inflammatory activity) and indomethacin did...
  39. pmc Image-derived input function for human brain using high resolution PET imaging with [C](R)-rolipram and [C]PBR28
    Paolo Zanotti-Fregonara
    Molecular Imaging Branch, National Institute of Mental Health NIMH, National Institutes of Health NIH, Bethesda, Maryland, United States of America
    PLoS ONE 6:e17056. 2011
    ..Three of the methods required arterial blood samples to scale the image-input, and four were blood-free methods...
  40. pmc Population-based input function and image-derived input function for [¹¹C](R)-rolipram PET imaging: methodology, validation and application to the study of major depressive disorder
    Paolo Zanotti-Fregonara
    Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA
    Neuroimage 63:1532-41. 2012
    ..the use of a population-based input function (PBIF) and an image-derived input function (IDIF) for [(11)C](R)-rolipram kinetic analysis, with the goal of reducing - and possibly eliminating - the number of arterial blood samples ..
  41. doi The flavonoid dioclein reduces the production of pro-inflammatory mediators in vitro by inhibiting PDE4 activity and scavenging reactive oxygen species
    Rodrigo Guabiraba
    Laboratorio de Imunofarmacologia, Departamento de Bioquímica e Imunologia ICB, Universidade Federal de Minas Gerais, Av Antonio Carlos, 6627 Pampulha, 31270 901, Belo Horizonte MG, Brazil
    Eur J Pharmacol 633:85-92. 2010
    ..Murine macrophages were pretreated with dioclein, rolipram, a PDE4 (cyclic nucleotide phosphosdiesterase type 4) inhibitor, or butylated hydroxytoluene (BHT), an ..
  42. ncbi Noradrenergic lesions differentially alter the expression of two subtypes of low Km cAMP-sensitive phosphodiesterase type 4 (PDE4A and PDE4B) in rat brain
    S M Farooqui
    Department of Pharmacology and Therapeutics, Louisiana State University Medical Center, Shreveport, LA 71130, USA
    Brain Res 867:52-61. 2000
    ..These data demonstrate that PDE4 subtypes are differentially regulated by presynaptic noradrenergic activity and may play an important role in the maintaining homeostasis of noradrenergic signal transduction in rat brain...
  43. ncbi Luteolin, a non-selective competitive inhibitor of phosphodiesterases 1-5, displaced [3H]-rolipram from high-affinity rolipram binding sites and reversed xylazine/ketamine-induced anesthesia
    Ming Chih Yu
    Department of Internal Medicine, Taipei Municipal Wan Fang Hospital, Taiwan
    Eur J Pharmacol 627:269-75. 2010
    ..possible adverse effects, such as nausea, vomiting, and gastric hypersecretion, determined by replacing [(3)H]-rolipram binding and reversing xylazine/ketamine-induced anesthesia...
  44. pmc Inflammation, mucous cell metaplasia, and Bcl-2 expression in response to inhaled lipopolysaccharide aerosol and effect of rolipram
    Kevin R Smith
    COPD Program, Lovelace Respiratory Research Institute, Albuquerque, NM 87108, USA
    Toxicol Appl Pharmacol 253:253-60. 2011
    ..When rats were treated with the phosphodiesterase-4 (PDE4) inhibitor, rolipram (10mg/kg), prior to exposure to aerosolized LPS neutrophil numbers in the BAL were reduced at 8h but not at 24 or ..
  45. pmc Rolipram inhibits leukocyte-endothelial cell interactions in vivo through P- and E-selectin downregulation
    Maria Jesus Sanz
    Department of Pharmacology, Faculty of Medicine, University of Valencia, Spain
    Br J Pharmacol 135:1872-81. 2002
    1. Rolipram, a selective phosphodiesterase (PDE) type 4 inhibitor, was used to characterize leukocyte recruitment mechanisms in models of acute and subacute inflammation...
  46. ncbi Effects of rolipram, pimobendan and zaprinast on ischaemia-induced dysrhythmias and on ventricular cyclic nucleotide content in the anaesthetized rat
    M D Carceles
    University School of Medicine, Department of Anaesthesiology, CSV Arrixaca Hospital, Murcia, Spain
    Eur J Anaesthesiol 20:205-11. 2003
    ..The drugs used were pimobendan, a selective PDE III inhibitor, rolipram, a selective PDE IV inhibitor, and zaprinast, a selective PDE V inhibitor.
  47. pmc Antidepressant- and anxiolytic-like effects of the phosphodiesterase-4 inhibitor rolipram on behavior depend on cyclic AMP response element binding protein-mediated neurogenesis in the hippocampus
    Yun Feng Li
    Department of Behavioral Medicine and Psychiatry, West Virginia University Health Sciences Center, Morgantown, WV 26506 9137, USA
    Neuropsychopharmacology 34:2404-19. 2009
    ..In this study, chronic administration of rolipram (0.31-1.25 mg/kg, 16-23 days) produced antidepressant- and anxiolytic-like effects on behavior in mice...
  48. ncbi The phosphodiesterase type 4 inhibitor, rolipram, enhances glucocorticoid receptor function
    Andrew H Miller
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 1639 Pierce Dr, Suite 4000, Atlanta, GA 30322, USA
    Neuropsychopharmacology 27:939-48. 2002
    ..Accordingly, we examined GR function in cells treated with rolipram, a phosphodiesterase (PDE) type 4 inhibitor that antagonizes cAMP breakdown...
  49. pmc Whole-body biodistribution and radiation dosimetry in monkeys and humans of the phosphodiesterase 4 radioligand [(11)C](R)-rolipram: comparison of two-dimensional planar, bisected and quadrisected image analyses
    David R Sprague
    Molecular Imaging Branch, National Institute of Mental Health, Bethesda, MD 20892 2035, USA
    Nucl Med Biol 35:493-500. 2008
    11)C](R)-Rolipram is a selective radioligand for positron emission tomography (PET) imaging of phosphodiesterase 4, an enzyme that metabolizes 3',5'-cyclic adenosine monophosphate...
  50. ncbi Improved sensorimotor function by rolipram following focal cerebral ischemia in rats
    Sonja Hätinen
    Department of Neurology, University of Kuopio, Finland
    Restor Neurol Neurosci 26:493-9. 2008
    b>Rolipram, a specific phosphodiesterase 4 inhibitor (PDE4), is suggested to facilitate functional recovery following brain injury by activation of cAMP/CREB pathway...
  51. ncbi Effect of phosphodiesterase inhibitor-4, rolipram, on new bone formations by recombinant human bone morphogenetic protein-2
    H Horiuchi
    Department of Orthopaedic Surgery, Shinshu University School of Medicine, Nagano, Japan
    Bone 30:589-93. 2002
    ..Ten or 20 mg/kg per day of Rolipram, a selective inhibitory agent to phosphodiesterase type 4 (PDE-4), or vehicle, was injected subcutaneously into ..
  52. ncbi Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors
    Ana Castro
    Instituto de Química Médica, Juan de la Cierva 3, 28006 Madrid, Spain
    Med Res Rev 25:229-44. 2005
    ..The review also highlights the novel structural classes of PDE4 and PDE7 inhibitors, and the therapeutic potential that combined PDE4/PDE7 inhibitors offer as immunomodulatory agents...
  53. ncbi Preventive effect of rolipram, a phosphodiesterase 4 enzyme inhibitor, on oxidative renal injury in acute ascending pyelonephritis model in rats
    Sadik Gorur
    Department of Urology, Mustafa Kemal University Faculty of Medicine, Antioch Hatay, Turkey
    Urology 72:743-8. 2008
    To evaluate the effects of rolipram, a phosphodiesterase 4 enzyme inhibitor, on Escherichia coli-induced renal oxidative damage in an acute pyelonephritis (PYN) rat model.
  54. ncbi Comparision of the inotropic effects of levosimendan, rolipram, and dobutamine on human atrial trabeculae
    Coskun Usta
    Department of Pharmacology, Akdeniz University, Medical Faculty, Antalya, Turkey
    J Cardiovasc Pharmacol 44:622-5. 2004
    ..compare the positive inotropic effects of 3 different agents with 3 different mechanisms of actions-levosimendan, rolipram, and dobutamine-on human atrial trabecular muscles...
  55. pmc The phosphodiesterase inhibitor rolipram delivered after a spinal cord lesion promotes axonal regeneration and functional recovery
    Elena Nikulina
    Biology Department, Hunter College, City University of New York, New York, NY 10024, USA
    Proc Natl Acad Sci U S A 101:8786-90. 2004
    ..We now show that the phosphodiesterase 4 (PDE4) inhibitor rolipram (which readily crosses the blood-brain barrier) overcomes inhibitors of regeneration in myelin in culture and ..
  56. ncbi Attenuation of the activity of the cAMP-specific phosphodiesterase PDE4A5 by interaction with the immunophilin XAP2
    Graeme B Bolger
    Veterans Affairs Medical Center, Huntsman Cancer Institute, Department of Medicine, Division of Oncology, University of Utah Health Sciences Center, Salt Lake City, Utah 84148, USA
    J Biol Chem 278:33351-63. 2003
    ..PDE4A5 to inhibition by the prototypical PDE4 inhibitor 4-[3-(cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidinone (rolipram) and attenuated the ability of cAMP-dependent protein kinase to phosphorylate PDE4A5 in intact cells...
  57. ncbi Hydrolysis of N-methyl-D-aspartate receptor-stimulated cAMP and cGMP by PDE4 and PDE2 phosphodiesterases in primary neuronal cultures of rat cerebral cortex and hippocampus
    Neesha U Suvarna
    Department of Pharmacology, University of Tennessee Health Science Center, 315 Crowe Building, 974 Union Avenue, Memphis, TN 38163, USA
    J Pharmacol Exp Ther 302:249-56. 2002
    ..However, among the family-selective inhibitors, only the PDE4 inhibitor rolipram enhanced the ability of NMDA to increase cAMP in the neurons...
  58. pmc Rolipram attenuates acute oligodendrocyte death in the adult rat ventrolateral funiculus following contusive cervical spinal cord injury
    Christopher M Whitaker
    Kentucky Spinal Cord Injury Research Center, School of Medicine, University of Louisville, Louisville, KY 40292, USA
    Neurosci Lett 438:200-4. 2008
    b>Rolipram, an inhibitor of phosphodiesterase 4 (PDE4) proteins that hydrolyze cAMP, increases axonal regeneration following spinal cord injury (SCI)...
  59. ncbi Dysregulation of protein kinase a signaling in the aged prefrontal cortex: new strategy for treating age-related cognitive decline
    Brian P Ramos
    Department of Neurobiology, Yale University School of Medicine, New Haven, CT 06510, USA
    Neuron 40:835-45. 2003
    ..These data demonstrate that PKA inhibition, rather than activation, is the appropriate strategy for restoring prefrontal cortical cognitive abilities in the elderly...
  60. ncbi The type IV phosphodiesterase inhibitor rolipram induces expression of the cell cycle inhibitors p21(Cip1) and p27(Kip1), resulting in growth inhibition, increased differentiation, and subsequent apoptosis of malignant A-172 glioma cells
    Thomas C Chen
    LAC USC Medical Center, Department of Neurosurgery, Pathology, University of Southern California, 1200 N State St, Suite 5046, Los Angeles, CA 90033, USA
    Cancer Biol Ther 1:268-76. 2002
    ..Therefore, we investigated the effects of rolipram, a drug that has undergone clinical trials as an antidepressant and has also been proposed as a treatment for ..
  61. ncbi Genistein, a competitive PDE1-4 inhibitor, may bind on high-affinity rolipram binding sites of brain cell membranes and then induce gastrointestinal adverse effects
    Chung Hong Shih
    Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan
    Eur J Pharmacol 643:113-20. 2010
    ..3 to 13.7 microM. Genistein (3-300 microM) concentration-dependently displaced 2nM [(3)H]-rolipram bound on high-affinity rolipram binding sites of brain cell membranes...
  62. ncbi Localization of phosphorylated cAMP response element-binding protein in immature neurons of adult hippocampus
    Shin Nakagawa
    Division of Molecular Psychiatry, Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, Yale University School of Medicine, New Haven, Connecticut 06508, USA
    J Neurosci 22:9868-76. 2002
    ..These findings indicate that the cAMP-CREB pathway regulates the survival, and possibly the differentiation and function, of newborn neurons...
  63. pmc Rolipram-induced elevation of cAMP or chondroitinase ABC breakdown of inhibitory proteoglycans in the extracellular matrix promotes peripheral nerve regeneration
    E Udina
    Division of Physical Medicine and Rehabilitation, Faculty of Medicine and Dentistry, Center for Neurosciences, University of Alberta, Edmonton, Alberta, Canada T6G 2S2
    Exp Neurol 223:143-52. 2010
    ..transected common peroneal (CP) nerve in rats and either elevated cAMP in the axotomized neurons by subcutaneous rolipram, a specific inhibitor of phosphodiesterase IV, and/or promoted degradation of proteoglycans in the distal nerve ..
  64. ncbi cAMP and Schwann cells promote axonal growth and functional recovery after spinal cord injury
    Damien D Pearse
    The Miami Project to Cure Paralysis, University of Miami School of Medicine, 1095 NW 14th Terrace, Miami, Florida 33136, USA
    Nat Med 10:610-6. 2004
    ..Inhibition of cAMP hydrolysis by the phosphodiesterase IV inhibitor rolipram prevents this decrease and when combined with Schwann cell grafts promotes significant supraspinal and ..
  65. pmc The role of the PDE4D cAMP phosphodiesterase in the regulation of glucagon-like peptide-1 release
    W K Ong
    Strathclyde Institute of Pharmacy, Cell Biology Group, University of Strathclyde, Glasgow, UK
    Br J Pharmacol 157:633-44. 2009
    ..As cAMP is hydrolysed by cAMP phosphodiesterases (PDEs), we determined the role of PDEs and particularly PDE4 in regulating GLP-1 release...
  66. ncbi Early and late bronchoconstrictions, airway hyper-reactivity, leucocyte influx and lung histamine and nitric oxide after inhaled antigen: effects of dexamethasone and rolipram
    T J Toward
    Division of Pharmacology, Welsh School of Pharmacy, Cardiff University, Cardiff, UK
    Clin Exp Allergy 34:91-102. 2004
    ....
  67. pmc The PDE4 inhibitor rolipram reverses object memory impairment induced by acute tryptophan depletion in the rat
    K Rutten
    Department of Psychiatry and Neuropsychology, Brain and Behavior Institute, Maastricht University, Universiteitssingel 50, 6200 MD, Maastricht, The Netherlands
    Psychopharmacology (Berl) 192:275-82. 2007
    The selective type IV phosphodiesterase inhibitor, rolipram, has been shown to improve long-term memory and can reverse the cholinergic deficit caused by scopolamine. However, the underlying mechanisms of action of rolipram remain obscure.
  68. ncbi Difference in preventive effects between the phosphodiesterase iv inhibitor rolipram and anti-arthritic drugs on antigen-induced arthritis in mice
    Kouya Yamaki
    Department of Pharmacology, Kobe Pharmaceutical University, Kobe, Hyogo, Japan
    Immunol Invest 36:131-45. 2007
    The efficacy of the phosphodiesterase (PDE) IV inhibitor rolipram on antigen-induced arthritis (AIA) in mice was evaluated in comparison with clinically used anti-arthritic drugs...
  69. ncbi Three-dimensional structures of PDE4D in complex with roliprams and implication on inhibitor selectivity
    Qing Huai
    Department of Biochemistry and Biophysics and Lineberger Comprehensive Cancer Center, The University of North Carolina, Chapel Hill, Chapel Hill, NC 27599, USA
    Structure 11:865-73. 2003
    ..The crystal structures of the PDE4D2 catalytic domain in complex with (R)- or (R,S)-rolipram suggest that inhibitor selectivity is determined by the chemical nature of amino acids and subtle conformational ..
  70. pmc Selective PDE inhibitors rolipram and sildenafil improve object retrieval performance in adult cynomolgus macaques
    K Rutten
    Department of Neuroscience, School for Mental Health and Neuroscience, Maastricht University, Universiteitssingel 50, PO Box 616, 6200 MD Maastricht, The Netherlands
    Psychopharmacology (Berl) 196:643-8. 2008
    ..However, studies evaluating the effects of PDE inhibition on prefrontal cortex-dependent cognition and in monkeys are rare...
  71. pmc Combined medication of lovastatin with rolipram suppresses severity of experimental autoimmune encephalomyelitis
    Ajaib S Paintlia
    Darby Children s Research Institute, Medical University of South Carolina, USA
    Exp Neurol 214:168-80. 2008
    ..Another drug, rolipram (phosphodiesterase-4 inhibitor) ameliorates the clinical severity of EAE via induction of various anti-..
  72. ncbi Different regulation of adenylyl cyclase and rolipram-sensitive phosphodiesterase activity on the frontal cortex and hippocampus in learned helplessness rats
    Tetsuji Itoh
    Department of Drug Safety Evaluation, Developmental Research Laboratories, Shionogi and Co, Ltd, 3 1 1, Futaba cho, Toyonaka, Osaka 561 0825, Japan
    Brain Res 991:142-9. 2003
    The present study examined the activities of adenylyl cyclase (AC) and rolipram-sensitive phosphodiesterase (PDE4) on brain regions in learned helplessness rat in order to clarify the cyclic AMP (cAMP) regulation system in the depressive ..
  73. ncbi Rolipram inhibits polarization and migration of human T lymphocytes
    Esther Layseca-Espinosa
    Departamento de Inmunologia, Facultad de Medicina, Universidad Autonoma de San Luis Potosi, Mexico
    J Invest Dermatol 121:81-7. 2003
    ..skin diseases; however, an overall study on the effects of specific phosphodiesterase inhibitors, such as rolipram on the processes involved in the extravasation of lymphoid cells has not been performed...
  74. ncbi Upregulation of phosphodiesterase-4 in the lung of allergic rats
    Hui Fang Tang
    Schering Plough Research Institute, 2015 Galloping Hill Road, K 15 1600, Kenilworth, NJ 07033, USA
    Am J Respir Crit Care Med 171:823-8. 2005
    ..The increases in pulmonary resistance and IL-4 production were both suppressed by the PDE4-selective inhibitor rolipram or the corticosteroid drug dexamethasone...
  75. ncbi Cellular mechanisms underlying prostaglandin-induced transient cAMP signals near the plasma membrane of HEK-293 cells
    Thomas C Rich
    Department of Pharmacology, College of Medicine and Center for Lung Biology, University of South Alabama, Mobile, AL 36688, USA
    Am J Physiol Cell Physiol 292:C319-31. 2007
    ..Following pretreatment with rolipram (a PDE4 inhibitor), H89 had little or no effect on near-membrane or total cAMP levels...
  76. ncbi Phosphodiesterase inhibitors: a novel mechanism for receptor-independent antipsychotic medications
    C R Maxwell
    Stanley Center for Experimental Therapeutics in Psychiatry, Division of Neuropsychiatry, Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA
    Neuroscience 129:101-7. 2004
    ..The current study examines the potential of using non-receptor-based agents that modify intracellular signal transduction as potential antipsychotic medications...
  77. ncbi Selective inhibition of purified human phosphodiesterase 4A expressed in yeast cell GL62 by ciclamilast, piclamilast, and rolipram
    Jun Chun Chen
    Respiratory Drugs Research Laboratory of State Food and Drugs Administration of China, Medical School of Zhejiang University, Hangzhou 310031, China
    Acta Pharmacol Sin 25:1171-5. 2004
    ..and investigate the effects of selective phosphodiesterase 4 (PDE4) inhibitors (ciclamilast, piclamilast, and rolipram), selective phosphodiesterase 5 (PDE5) inhibitor zaprinast, and cyclooxygenase (COX) inhibitors (aspirin, ..
  78. ncbi Effects of rolipram, a selective inhibitor of type 4 phosphodiesterase, on lipopolysaccharide-induced uveitis in rats
    Zai Long Chi
    Department of Ophthalmology, Toyama Medical and Pharmaceutical University, Sugitani, Toyama, Japan
    Invest Ophthalmol Vis Sci 45:2497-502. 2004
    To investigate effects of rolipram, an inhibitor of type 4 phosphodiesterase, on lipopolysaccharide (LPS)-induced uveitis in Wistar rats.
  79. ncbi Elastolytic activity and alveolar epithelial type-1 cell damage after chronic LPS inhalation: effects of dexamethasone and rolipram
    Frederick J Johnson
    Division of Pharmacology, Welsh School of Pharmacy, Cardiff University, King Edward VII Avenue, Cathays Park, Cardiff, CF10 3XF, UK
    Toxicol Appl Pharmacol 207:257-65. 2005
    ..The effect of the corticosteroid, dexamethasone, or the phosphodiesterase-4 (PDE4)-inhibitor, rolipram, on these features was studied...
  80. ncbi Effects of the phosphodiesterase IV inhibitor rolipram on Th1 and Th2 immune responses in mice
    Kouya Yamaki
    Department of Pharmacology, Kobe Pharmaceutical University, Kobe, Hyogo 658 8558, Japan
    J Pharm Pharmacol 56:877-82. 2004
    The present study was designed to investigate the effect of the phosphodiesterase IV inhibitor rolipram on Th1 and Th2 immune responses in mice...
  81. ncbi Rolipram reverses scopolamine-induced and time-dependent memory deficits in object recognition by different mechanisms of action
    K Rutten
    Department of Psychiatry and Neuropsychology, Brain and Behaviour Institute, Maastricht University, PO Box 616, 6200 MD Maastricht, The Netherlands
    Neurobiol Learn Mem 85:132-8. 2006
    In this study, the effect of the selective phosphodiesterase type 4 (PDE4) inhibitor rolipram on memory performance was investigated using the object recognition task. First, three doses of rolipram (0.01, 0.03 or 0...
  82. ncbi Mitogen-activated protein kinase-mediated reinforcement of hippocampal early long-term depression by the type IV-specific phosphodiesterase inhibitor rolipram and its effect on synaptic tagging
    Sheeja Navakkode
    Department of Neurophysiology, Leibniz Institute for Neurobiology, D 39118 Magdeburg, Germany
    J Neurosci 25:10664-70. 2005
    b>Rolipram, a selective inhibitor of cAMP-specific phosphodiesterase 4 (PDE4), has been shown to reinforce an early form of long-term potentiation (LTP) to a long-lasting LTP (late LTP)...
  83. ncbi Inhibition of the phosphodiesterase 4 (PDE4) enzyme reverses memory deficits produced by infusion of the MEK inhibitor U0126 into the CA1 subregion of the rat hippocampus
    Han Ting Zhang
    Department of Pharmacology, The University of Tennessee Health Science Center, Memphis, TN 38163, USA
    Neuropsychopharmacology 29:1432-9. 2004
    ..It was found that rolipram, a PDE4-selective inhibitor, reversed the amnesic effect in the radial-arm maze test of the MEK inhibitor U0126 ..
  84. pmc Phosphodiesterase-4 influences the PKA phosphorylation status and membrane translocation of G-protein receptor kinase 2 (GRK2) in HEK-293beta2 cells and cardiac myocytes
    Xiang Li
    Molecular Pharmacology Group, Division of Biochemistry and Molecular Biology, IBLS, Wolfson Link Building, University of Glasgow, University Avenue, Glasgow G12 8QQ, Scotland, UK
    Biochem J 394:427-35. 2006
    ..when cAMP-specific PDE4 (phosphodiesterase-4) activity is selectively inactivated, either chemically with rolipram or by siRNA (small interfering RNA)-mediated knockdown of PDE4B and PDE4D...
  85. ncbi Adenovirus-mediated delivery and expression of a cAMP-dependent protein kinase inhibitor gene to BEAS-2B epithelial cells abolishes the anti-inflammatory effects of rolipram, salbutamol, and prostaglandin E2: a comparison with H-89
    Koremu K Meja
    Thoracic Medicine, National Heart and Lung Institute, Imperial College London, London, United Kingdom
    J Pharmacol Exp Ther 309:833-44. 2004
    ..antagonized MCP-1-induced [(3)H]AA release and enhanced the inhibitory effect of submaximal concentrations of rolipram and 8-bromo-cAMP...
  86. ncbi Increasing synaptic noradrenaline, serotonin and histamine enhances in vivo binding of phosphodiesterase-4 inhibitor (R)-[11C]rolipram in rat brain, lung and heart
    Celia M Lourenco
    PET Centre, Centre for Addiction and Mental Health, 250 College St, Toronto, Ontario, Canada M5T 1R8
    Life Sci 79:356-64. 2006
    ..PDE4 expression and activity are modulated by agents affecting cAMP levels. The selective PDE4 inhibitor (R)-rolipram labeled with C-11 was tested in vivo in rats to analyze changes in PDE4 levels following drug treatments that ..
  87. pmc Impact of VIP and cAMP on the regulation of TNF-alpha and IL-10 production: implications for rheumatoid arthritis
    Andrew D Foey
    Kennedy Institute of Rheumatology Division, Charing Cross Hospital Campus, Imperial College School of Medicine, London, UK
    Arthritis Res Ther 5:R317-28. 2003
    ..its slight effect on TNF-alpha results from cAMP being rapidly degraded as the phosphodiesterase IV inhibitor, rolipram, rescues cAMP-dependent activation of cAMP response element binding protein...
  88. ncbi The human cyclic AMP-specific phosphodiesterase PDE-46 (HSPDE4A4B) expressed in transfected COS7 cells occurs as both particulate and cytosolic species that exhibit distinct kinetics of inhibition by the antidepressant rolipram
    E Huston
    Molecular Pharmacology Group, Division of Biochemistry and Molecular Biology, IBLS, Wolfson Link Building, University of Glasgow, Glasgow G12 8QQ, Scotland, United Kingdom
    J Biol Chem 271:31334-44. 1996
    ..encoding the human cyclic AMP-specific PDE4A phosphodiesterase PDE-46 (HSPDE4A4B) led to the expression of a rolipram-inhibited PDE4 activity, which contributed approximately 96% of the total COS cell PDE activity...
  89. ncbi Modulation of corneal endothelial hydration control mechanisms by Rolipram
    C G Wigham
    Department of Optometry and Vision Sciences, Cardiff University, UK
    Pflugers Arch 440:866-70. 2000
    ..To resolve this question, the effects of Rolipram, a cAMP phosphodiesterase inhibitor, on endothelial physiology were determined. Addition of 0...
  90. ncbi The phosphodiesterase inhibitors pentoxifylline and rolipram suppress macrophage activation and nitric oxide production in vitro and in vivo
    E Beshay
    The Department of Pathology, McGill University, 3775 University Street, Montreal, Quebec, H3A 2B4, Canada
    Clin Immunol 98:272-9. 2001
    We studied the effects of the phosphodiesterase inhibitors pentoxifylline (PTX) and rolipram (ROL) on nitric oxide (NO) production by macrophages and correlated this with cellular cAMP levels. The RAW 264...
  91. ncbi Effects of rolipram on scopolamine-induced impairment of working and reference memory in the radial-arm maze tests in rats
    H T Zhang
    Department of Pharmacology and Therapeutics, Louisiana State University Medical Center, Shreveport 71130, USA
    Psychopharmacology (Berl) 150:311-6. 2000
    b>Rolipram, a selective inhibitor of cyclic AMP-specific phosphodiesterase (PDE4), has been shown to enhance scopolamine-induced impairment of working memory...
  92. pmc Effects of a phosphodiesterase IV inhibitor rolipram on microsphere embolism-induced defects in memory function and cerebral cyclic AMP signal transduction system in rats
    Akira Nagakura
    Department of Pharmacology, Tokyo University of Pharmacy and Life Science, 1432 1, Horinouchi, Hachioji, Tokyo 192 0392, Japan
    Br J Pharmacol 135:1783-93. 2002
    The effects of treatment with rolipram, a specific phosphodiesterase IV inhibitor, on learning and memory function and on the cyclic AMP/PKA/CREB signal transduction system were examined in rats with microsphere embolism (ME)-induced ..
  93. ncbi Inhibition of cyclic AMP phosphodiesterase (PDE4) reverses memory deficits associated with NMDA receptor antagonism
    H T Zhang
    Department of Pharmacology and Therapeutics, Louisiana State University Medical Center, Shreveport, LA 71130, USA
    Neuropsychopharmacology 23:198-204. 2000
    b>Rolipram, a selective inhibitor of type 4 cyclic AMP phosphodiesterase (PDE4), completely reversed the amnesic effects of MK-801 on working and reference memory (F[4,64] = 11.10; p <.0001 and F[4,64] = 2.53; p <...
  94. pmc Characterization of five different proteins produced by alternatively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D gene
    G B Bolger
    Department of Veterans Affairs Medical Center, 151M, and Huntsman Cancer Institute, Department of Oncologic Sciences and Department of Medicine Hematology Oncology University of Utah Health Sciences Center, Salt Lake City, UT 84148, USA
    Biochem J 328:539-48. 1997
    ..two isoforms (HSPDE4D4 and HSPDE4A5) encoded by the human PDE4D gene, one of four genes that encode cAMP-specific rolipram-inhibited 3',5'-cyclic nucleotide phosphodiesterases (type IVPDEs; PDE4 family)...
  95. ncbi Phosphodiesterase type 4 isozymes expression in human brain examined by in situ hybridization histochemistry and[3H]rolipram binding autoradiography. Comparison with monkey and rat brain
    S Pérez-Torres
    Department of Neurochemistry, Instituto de Investigaciones Biomédicas de Barcelona, CSIC IDIBAPS, C Rosselló 161, 6a, E 08036, Barcelona, Spain
    J Chem Neuroanat 20:349-74. 2000
    ..mRNAs in the brain of different species by in situ hybridization histochemistry and by autoradiography with [3H]rolipram. We have compared the localization of each isozyme in human brain with that in rat and monkey brain...
  96. ncbi Diazepam and rolipram differentially inhibit cyclic AMP-specific phosphodiesterases PDE4A1 and PDE4B3 in the mouse
    J A Cherry
    Department of Psychology and Laboratory of Molecular Neurobiology and Behavior, 64 Cummington Street, Boston University, 02215, Boston, MA, USA
    Biochim Biophys Acta 1518:27-35. 2001
    ..by benzodiazepines, it has not been conclusively demonstrated that members of the class of cyclic AMP-specific, rolipram-inhibitable PDEs (PDE4s) are targets for these drugs...
  97. ncbi A low-Km, rolipram-sensitive, cAMP-specific phosphodiesterase from human brain. Cloning and expression of cDNA, biochemical characterization of recombinant protein, and tissue distribution of mRNA
    M M McLaughlin
    Department of Gene Expression Sciences, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406
    J Biol Chem 268:6470-6. 1993
    ..of the expected kinetic characteristics for a PDE IV, including sensitivity to the isozyme-selective inhibitor rolipram (Ki = 0.085 microM)...
  98. ncbi Comparison of PDE 4 inhibitors, rolipram and SB 207499 (ariflo), in a rat model of pulmonary neutrophilia
    J Spond
    Schering Plough Research Institute, Kenilworth, New Jersey, USA
    Pulm Pharmacol Ther 14:157-64. 2001
    ..of SB 207499 was evaluated and compared to that of the prototypic type-4 phosphodiesterase (PDE4) inhibitor, rolipram. In dose-response experiments, we found that rats exposed to 10 microg or 100 microg of intratracheal (it) LPS ..
  99. ncbi Rolipram depresses [(3)H]2-deoxyglucose uptake in mouse brain and heart in vivo
    Megumi Ishikawa
    Department of Medical Physics, School of Allied Health Sciences, Faculty of Medicine, Osaka University, 1 7 Yamadaoka, Suita Shi, Osaka, Japan
    Eur J Nucl Med Mol Imaging 29:1212-5. 2002
    The effects of systemic administration of rolipram, a selective phosphodiesterase type 4 inhibitor, on [(3)H]2-deoxyglucose (DG) uptake in brain and peripheral tissues were examined...
  100. ncbi Goblet cell hyperplasia, airway function, and leukocyte infiltration after chronic lipopolysaccharide exposure in conscious Guinea pigs: effects of rolipram and dexamethasone
    Toby J Toward
    Division of Pharmacology, Welsh School of Pharmacy, Cardiff University, King Edward VII Avenue, Cathays Park, Cardiff CF10 3XF, Wales, UK
    J Pharmacol Exp Ther 302:814-21. 2002
    ..parameters to treatment with the corticosteroid, dexamethasone, or the phosphodiesterase-4 (PDE4) inhibitor, rolipram, was determined...
  101. pmc Airway function, oedema, cell infiltration and nitric oxide generation in conscious ozone-exposed guinea-pigs: effects of dexamethasone and rolipram
    Toby J Toward
    Division of Pharmacology, Welsh School of Pharmacy, Cardiff University, King Edward VII Avenue, Cathays Park, Cardiff CF10 3XF
    Br J Pharmacol 136:735-45. 2002
    ..15+/-0.05 p.p.m.) and their modification by dexamethasone (20 mg kg(-1)) or the phosphodiesterase-4 inhibitor, rolipram (1 mg kg(-1)), administered (i.p.) 24 and 0...

Research Grants72

  1. PKA-Hypothermia Bridge: A New Therapeutic Approach for Traumatic Brain Injury
    Larry W Jenkins; Fiscal Year: 2010
    ..To this end, we found that the activation of PKA activity with Rolipram, (a type IV phosphodiesterase inhibitor [PDE4] which increases cAMP levels and PKA activation) and reduced ..
  2. HEMORHEOLOGICAL FACTORS IN CEREBRAL ISCHEMIA
    Mark Fisher; Fiscal Year: 2009
    ..the in vivo role of PDE4 and PDE4D in the brain microvascular response to endotoxin, using rats pretreated with rolipram and mice null for PDE4D...
  3. Up-regulation of Mucin Gene Transcription-Otitis Media
    Jian dong Li; Fiscal Year: 2010
    ..preliminary studies indicate that MKP-1 itself is further negatively controlled by phosphodiesterase 4B (PDE4B);Rolipram, a specific inhibitor of PDE4 that has been already in late phase III clinical trial for asthma and COPD, ..
  4. Gene silencing of phosphodiesterase-4D (PDE4D) as a therapeutic approach to beta
    Han Ting Zhang; Fiscal Year: 2009
    ..Primarily through this mechanism, the PDE4 inhibitor rolipram not only counteracts the inhibitory effects of high levels of amyloid-beta peptide (Abeta) on cAMP signaling and ..
  5. CRYSTAL STRUCT. OF CYCLIC NUCLEOTIDE PHOSPHODIESTERASE
    Hengming Ke; Fiscal Year: 2002
    ..including (1) the catalytic domain of PDE4B, (2) the catalytic domain of PDE4B complexed with the inhibitors rolipram and iodonated cAMP, (3) full length PDE4D and its complexes with the inhibitors rolipram and denbufylline and (4) ..
  6. CRYSTAL STRUCT. OF CYCLIC NUCLEOTIDE PHOSPHODIESTERASE
    Hengming Ke; Fiscal Year: 2000
    ..including (1) the catalytic domain of PDE4B, (2) the catalytic domain of PDE4B complexed with the inhibitors rolipram and iodonated cAMP, (3) full length PDE4D and its complexes with the inhibitors rolipram and denbufylline and (4) ..
  7. CRYSTAL STRUCT. OF CYCLIC NUCLEOTIDE PHOSPHODIESTERASE
    Hengming Ke; Fiscal Year: 2001
    ..including (1) the catalytic domain of PDE4B, (2) the catalytic domain of PDE4B complexed with the inhibitors rolipram and iodonated cAMP, (3) full length PDE4D and its complexes with the inhibitors rolipram and denbufylline and (4) ..
  8. CRYSTAL STRUCT. OF CYCLIC NUCLEOTIDE PHOSPHODIESTERASE
    Hengming Ke; Fiscal Year: 2003
    ..including (1) the catalytic domain of PDE4B, (2) the catalytic domain of PDE4B complexed with the inhibitors rolipram and iodonated cAMP, (3) full length PDE4D and its complexes with the inhibitors rolipram and denbufylline and (4) ..
  9. Effects of Lead on Cortical Development and Plasticity
    Mary Wilson; Fiscal Year: 2006
    ..be blocked by the NMDA antagonist dextromethorphan, inhibition of Ras with FPT III, or inhibition of PDE4 with rolipram, 3) to determine whether postnatal lead exposure increases or decreases phosphorylation of CREB, ERK1/2 or CaMKIV ..
  10. Effects of Lead on Cortical Development and Plasticity
    MARY A WILSON; Fiscal Year: 2010
    ..be blocked by the NMDA antagonist dextromethorphan, inhibition of Ras with FPT III, or inhibition of PDE4 with rolipram, 3) to determine whether postnatal lead exposure increases or decreases phosphorylation of CREB, ERK1/2 or CaMKIV ..
  11. Effects of Lead on Cortical Development and Plasticity
    Mary Wilson; Fiscal Year: 2009
    ..be blocked by the NMDA antagonist dextromethorphan, inhibition of Ras with FPT III, or inhibition of PDE4 with rolipram, 3) to determine whether postnatal lead exposure increases or decreases phosphorylation of CREB, ERK1/2 or CaMKIV ..
  12. Effects of Lead on Cortical Development and Plasticity
    Mary Wilson; Fiscal Year: 2007
    ..be blocked by the NMDA antagonist dextromethorphan, inhibition of Ras with FPT III, or inhibition of PDE4 with rolipram, 3) to determine whether postnatal lead exposure increases or decreases phosphorylation of CREB, ERK1/2 or CaMKIV ..
  13. REGULATION OF ADULT NEUROGENESIS--STRESS /ANTIDEPRESSANT
    Ronald Duman; Fiscal Year: 2002
    ..Preliminary studies demonstrate that administration of a drug which blocks cAMP metabolism (rolipram) increases, while over- expression of a dominant negative mutant of CREB decreases, neurogenesis in adult ..
  14. Novel A2A Adenosine Agonists in Vascular Protection
    Jayson Rieger; Fiscal Year: 2005
    ..combined used of two synergistic anti-inflammatory compounds, ATL146e, an agonist of A2A adenosine receptors, and rolipram, a type IV phosphodiesterase (PDE) inhibitor, loaded into a proprietary nanoporous stent coating, inhibits stent ..
  15. Novel A2A Adenosine Agonists in Vascular Protection
    Jayson Rieger; Fiscal Year: 2004
    ..combined used of two synergistic anti-inflammatory compounds, ATL146e, an agonist of A2A adenosine receptors, and rolipram, a type IV phosphodiesterase (PDE) inhibitor, loaded into a proprietary nanoporous stent coating, inhibits stent ..
  16. PKA-Hypothermia Bridge: A New Therapeutic Approach for Traumatic Brain Injury
    Larry Jenkins; Fiscal Year: 2009
    ..To this end, we found that the activation of PKA activity with Rolipram, (a type IV phosphodiesterase inhibitor [PDE4] which increases cAMP levels and PKA activation) and reduced ..
  17. HEMORHEOLOGICAL FACTORS IN CEREBRAL ISCHEMIA
    Mark Fisher; Fiscal Year: 2007
    ..the in vivo role of PDE4 and PDE4D in the brain microvascular response to endotoxin, using rats pretreated with rolipram and mice null for PDE4D...
  18. HEMORHEOLOGICAL FACTORS IN CEREBRAL ISCHEMIA
    Mark Fisher; Fiscal Year: 2009
    ..the in vivo role of PDE4 and PDE4D in the brain microvascular response to endotoxin, using rats pretreated with rolipram and mice null for PDE4D...
  19. HEMORHEOLOGICAL FACTORS IN CEREBRAL ISCHEMIA
    Mark J Fisher; Fiscal Year: 2010
    ..the in vivo role of PDE4 and PDE4D in the brain microvascular response to endotoxin, using rats pretreated with rolipram and mice null for PDE4D...
  20. Cyclic Nucleotide Regulation in Traumatic Brain Injury
    W Dalton Dietrich; Fiscal Year: 2009
    ..In other models of CMS injury, the phosphodiesterase (PDE) IV inhibitor rolipram, which prevents the degradation of cAMP, improves neuronal survival, axonal regeneration, and decreases ..
  21. Cyclic Nucleotide Regulation in Traumatic Brain Injury
    W DALTON DALTON DIETRICH; Fiscal Year: 2010
    ..In other models of CMS injury, the phosphodiesterase (PDE) IV inhibitor rolipram, which prevents the degradation of cAMP, improves neuronal survival, axonal regeneration, and decreases ..
  22. Cyclic Nucleotide Regulation in Traumatic Brain Injury
    W Dietrich; Fiscal Year: 2007
    ..In other models of CMS injury, the phosphodiesterase (PDE) IV inhibitor rolipram, which prevents the degradation of cAMP, improves neuronal survival, axonal regeneration, and decreases ..
  23. Cyclic Nucleotide Regulation in Traumatic Brain Injury
    W Dalton Dietrich; Fiscal Year: 2009
    ..In other models of CMS injury, the phosphodiesterase (PDE) IV inhibitor rolipram, which prevents the degradation of cAMP, improves neuronal survival, axonal regeneration, and decreases ..
  24. APOPTOSIS IN NORMAL AND MALIGNANT LYMPHOCYTES
    Adam Lerner; Fiscal Year: 2000
    ..CLL cells contained PDE4B transcript, protein and enzymatic activity. Inhibition of PDE4 by rolipram raised cAMP levels and induced apoptosis in CLL cells in a dose dependent fashion that required 48 hours to ..
  25. Regulation of CXCR4 by cognate and non-cognate ligands
    Elias Lolis; Fiscal Year: 2010
    ..in the glioblastoma mouse model required an increase on cAMP and that the cAMP phosphodiesterase inhibitor rolipram had similar therapeutic effects as CXCR4 antagonism due to an increase in cAMP...
  26. APOPTOSIS IN NORMAL AND MALIGNANT LYMPHOCYTES
    Adam Lerner; Fiscal Year: 2002
    ..CLL cells contained PDE4B transcript, protein and enzymatic activity. Inhibition of PDE4 by rolipram raised cAMP levels and induced apoptosis in CLL cells in a dose dependent fashion that required 48 hours to ..
  27. APOPTOSIS IN NORMAL AND MALIGNANT LYMPHOCYTES
    Adam Lerner; Fiscal Year: 2001
    ..CLL cells contained PDE4B transcript, protein and enzymatic activity. Inhibition of PDE4 by rolipram raised cAMP levels and induced apoptosis in CLL cells in a dose dependent fashion that required 48 hours to ..
  28. APOPTOSIS IN NORMAL AND MALIGNANT LYMPHOCYTES
    Adam Lerner; Fiscal Year: 2003
    ..CLL cells contained PDE4B transcript, protein and enzymatic activity. Inhibition of PDE4 by rolipram raised cAMP levels and induced apoptosis in CLL cells in a dose dependent fashion that required 48 hours to ..
  29. CYCLIC NUCLEOTIDE PHOSPHODIESTERASE IN ASTROGLIA
    VERGINE MADELIAN; Fiscal Year: 1991
    ..One of the PDE types is selectively inhibited by RO 20-1724 and Rolipram. Rolipram has been effectively used in treating major (DMS-III) and endogenous (ICD-9) depressions, suggesting ..
  30. Phosphodiesterase-inhibitors, vascular integrity and SCI
    Raymond J Grill; Fiscal Year: 2010
    ..We propose to determine whether acute treatment with 2 PDE-ls, a specific PDE4a-inhibitor called rolipram and a non- selective PDE-I known as pentoxifylline reduce protein extravasation following SCI;protecting the BSCB ..
  31. LPS-PEPTIDE INTERACTION IN BLADDER INFLAMMATION
    Ricardo Saban; Fiscal Year: 2003
    ..cystitis and that treatment with a proteosome inhibitor (lactacystin) or phosphodiestase 4 inhibitor (rolipram) blocks both the expression of NF-kB genes and inflammation...
  32. CYCLIC NUCLEOTIDE PHOSPHODIESTERASE IN ASTROGLIA
    VERGINE MADELIAN; Fiscal Year: 1992
    ..One of the PDE types is selectively inhibited by RO 20-1724 and Rolipram. Rolipram has been effectively used in treating major (DMS-III) and endogenous (ICD-9) depressions, suggesting ..
  33. Phosphodiesterase-inhibitors, vascular integrity and SCI
    Raymond Grill; Fiscal Year: 2007
    ..We propose to determine whether acute treatment with 2 PDE-ls, a specific PDE4a-inhibitor called rolipram and a non- selective PDE-I known as pentoxifylline reduce protein extravasation following SCI; protecting the ..
  34. Phosphodiesterase-inhibitors, vascular integrity and SCI
    Raymond Grill; Fiscal Year: 2009
    ..We propose to determine whether acute treatment with 2 PDE-ls, a specific PDE4a-inhibitor called rolipram and a non- selective PDE-I known as pentoxifylline reduce protein extravasation following SCI;protecting the BSCB ..
  35. Phosphodiesterase-inhibitors, vascular integrity and SCI
    Raymond Grill; Fiscal Year: 2006
    ..We propose to determine whether acute treatment with 2 PDE-ls, a specific PDE4a-inhibitor called rolipram and a non- selective PDE-I known as pentoxifylline reduce protein extravasation following SCI; protecting the ..
  36. The Role of Cyclic AMP in Alcohol Withdrawal and Mental Disease
    JULIA ANN CHESTER; Fiscal Year: 2010
    ..to explore the therapeutic potential of two promising drugs that raise intracellular cAMP levels, forskolin and rolipram, to reduce physical, cognitive, and emotional signs of alcohol withdrawal in mice...
  37. The Role of Cyclic AMP in Alcohol Withdrawal and Mental Disease
    JULIA CHESTER; Fiscal Year: 2009
    ..to explore the therapeutic potential of two promising drugs that raise intracellular cAMP levels, forskolin and rolipram, to reduce physical, cognitive, and emotional signs of alcohol withdrawal in mice...
  38. Prevention of Alcohol Neurotoxicity by PDE4 Inhibitor
    Bahri Karacay; Fiscal Year: 2010
    ..Thus, an inhibitor of PDE4 could protect neurons by activating the cAMP-PKA- CREB pathway. Rolipram is a specific inhibitor of PDE4...
  39. Cyclic AMP-mediated apoptosis in lymphoid malignancies
    Adam Lerner; Fiscal Year: 2007
    Inhibitors of type 4 cAMP phosphodiesterase (PDE4) such as rolipram-induced apoptosis in B cell chronic lymphocytic leukemia, even in the absence of exogenous pharmacologic agents that activate adenylate cyclase such as the diterpene ..
  40. Cyclic AMP-mediated apoptosis in lymphoid malignancies
    Adam Lerner; Fiscal Year: 2006
    Inhibitors of type 4 cAMP phosphodiesterase (PDE4) such as rolipram-induced apoptosis in B cell chronic lymphocytic leukemia, even in the absence of exogenous pharmacologic agents that activate adenylate cyclase such as the diterpene ..
  41. Modulation of the Cyclic AMP Pathway after Traumatic Brain Injury in Aged Animals
    COLEEN ATKINS; Fiscal Year: 2009
    ..Treatment with a phosphodiesterase (PDE) inhibitor, rolipram, to increase cAMP levels improves hippocampal synaptic plasticity and learning in the uninjured aged animal...
  42. Cyclic AMP-mediated apoptosis in lymphoid malignancies
    Adam Lerner; Fiscal Year: 2005
    Inhibitors of type 4 cAMP phosphodiesterase (PDE4) such as rolipram-induced apoptosis in B cell chronic lymphocytic leukemia, even in the absence of exogenous pharmacologic agents that activate adenylate cyclase such as the diterpene ..
  43. Cyclic AMP-mediated apoptosis in lymphoid malignancies
    Adam Lerner; Fiscal Year: 2009
    Inhibitors of type 4 cAMP phosphodiesterase (PDE4) such as rolipram-induced apoptosis in B cell chronic lymphocytic leukemia, even in the absence of exogenous pharmacologic agents that activate adenylate cyclase such as the diterpene ..
  44. Modulation of the Cyclic AMP Pathway after Traumatic Brain Injury in Aged Animals
    Coleen M Atkins; Fiscal Year: 2010
    ..Treatment with a phosphodiesterase (PDE) inhibitor, rolipram, to increase cAMP levels improves hippocampal synaptic plasticity and learning in the uninjured aged animal...
  45. Regulation of CXCR4 by cognate and non-cognate ligands
    Elias Lolis; Fiscal Year: 2009
    ..in the glioblastoma mouse model required an increase on cAMP and that the cAMP phosphodiesterase inhibitor rolipram had similar therapeutic effects as CXCR4 antagonism due to an increase in cAMP...
  46. Exploring the role of Phosphodiesterase 4A in axonal regeneration
    Benjamin Sachs; Fiscal Year: 2007
    ..Indeed, rolipram, an inhibitor of type four phosphodiesterases (PDE4s), the enzymes responsible for cAMP degradation, has been ..
  47. NEUROPSYCHOPHARMACOLOGY OF CYCLIC AMP PDE INHIBITORS
    JAMES O DONNELL; Fiscal Year: 1999
    ..inhibitors in rats in two behavioral tasks, behavior maintained under a DRL 72-sec schedule and a two-lever rolipram drug discrimination procedure, with their inhibition of recombinant rat PDE4A, PDE4B, PDE4C, and PDE4D...
  48. NEUROPSYCHOPHARMACOLOGY OF CYCLIC AMP PDE INHIBITORS
    JAMES O DONNELL; Fiscal Year: 2002
    ..inhibitors in rats in two behavioral tasks, behavior maintained under a DRL 72-sec schedule and a two-lever rolipram drug discrimination procedure, with their inhibition of recombinant rat PDE4A, PDE4B, PDE4C, and PDE4D...
  49. NEUROPSYCHOPHARMACOLOGY OF CYCLIC AMP PDE INHIBITORS
    JAMES O DONNELL; Fiscal Year: 2001
    ..inhibitors in rats in two behavioral tasks, behavior maintained under a DRL 72-sec schedule and a two-lever rolipram drug discrimination procedure, with their inhibition of recombinant rat PDE4A, PDE4B, PDE4C, and PDE4D...
  50. NEUROPSYCHOPHARMACOLOGY OF CYCLIC AMP PDE INHIBITORS
    JAMES O DONNELL; Fiscal Year: 2000
    ..inhibitors in rats in two behavioral tasks, behavior maintained under a DRL 72-sec schedule and a two-lever rolipram drug discrimination procedure, with their inhibition of recombinant rat PDE4A, PDE4B, PDE4C, and PDE4D...
  51. NEUROPSYCHOPHARMACOLOGY OF CYCLIC AMP PDE INHIBITORS
    JAMES O DONNELL; Fiscal Year: 2000
    ..inhibitors in rats in two behavioral tasks, behavior maintained under a DRL 72-sec schedule and a two-lever rolipram drug discrimination procedure, with their inhibition of recombinant rat PDE4A, PDE4B, PDE4C, and PDE4D...
  52. NEUROPSYCHOPHARMACOLOGY OF CYCLIC AMP PDE INHIBITORS
    JAMES O DONNELL; Fiscal Year: 2006
    Inhibitors of Type 4 cyclic AMP phosphodiesterase (PDE4), such as rolipram, produce both antidepressant-like and memory-enhancing effects in preclinical models...
  53. NEUROPSYCHOPHARMACOLOGY OF CYCLIC AMP PDE INHIBITORS
    JAMES O DONNELL; Fiscal Year: 2004
    Inhibitors of Type 4 cyclic AMP phosphodiesterase (PDE4), such as rolipram, produce both antidepressant-like and memory-enhancing effects in preclinical models...
  54. NEUROPSYCHOPHARMACOLOGY OF CYCLIC AMP PDE INHIBITORS
    JAMES O DONNELL; Fiscal Year: 2005
    Inhibitors of Type 4 cyclic AMP phosphodiesterase (PDE4), such as rolipram, produce both antidepressant-like and memory-enhancing effects in preclinical models...
  55. NEUROPSYCHOPHARMACOLOGY OF CYCLIC AMP PDE INHIBITORS
    JAMES O DONNELL; Fiscal Year: 2003
    Inhibitors of Type 4 cyclic AMP phosphodiesterase (PDE4), such as rolipram, produce both antidepressant-like and memory-enhancing effects in preclinical models...
  56. NEUROPSYCHOPHARMACOLOGY OF CYCLIC AMP PDE INHIBITORS
    JAMES O DONNELL; Fiscal Year: 2005
    Inhibitors of Type 4 cyclic AMP phosphodiesterase (PDE4), such as rolipram, produce both antidepressant-like and memory-enhancing effects in preclinical models...
  57. NEUROPSYCHOPHARMACOLOGY OF CYCLIC AMP PDE INHIBITORS
    JAMES O DONNELL; Fiscal Year: 2007
    Inhibitors of Type 4 cyclic AMP phosphodiesterase (PDE4), such as rolipram, produce both antidepressant-like and memory-enhancing effects in preclinical models...
  58. Intracellular calcium release channels and cardiac arrhythmias
    Andrew Marks; Fiscal Year: 2009
    ..that cannot be PKA phosphorylated, RyR2-S2808A, is protected against SCD induced by inhibition of PDE4 with rolipram. Close interactions with the Pis of Project 2 (R. Kass - voltage-gated ion channels) and Project 3 (W.J...
  59. EFFICIENT SYNTHESIS OF BIOACTIVE GAMMA LACTAMS
    KYUNG JUNG; Fiscal Year: 2003
    ..Our synthetic targets encompass lactacystin, pramanicin, statine, rolipram, epolactaene, and kainic acid...
  60. EFFICIENT SYNTHESIS OF BIOACTIVE GAMMA LACTAMS
    KYUNG JUNG; Fiscal Year: 2004
    ..Our synthetic targets encompass lactacystin, pramanicin, statine, rolipram, epolactaene, and kainic acid...
  61. EFFICIENT SYNTHESIS OF BIOACTIVE GAMMA LACTAMS
    KYUNG JUNG; Fiscal Year: 2002
    ..Our synthetic targets encompass lactacystin, pramanicin, statine, rolipram, epolactaene, and kainic acid...
  62. EFFICIENT SYNTHESIS OF BIOACTIVE GAMMA LACTAMS
    KYUNG JUNG; Fiscal Year: 2001
    ..Our synthetic targets encompass lactacystin, pramanicin, statine, rolipram, epolactaene, and kainic acid...
  63. EFFICIENT SYNTHESIS OF BIOACTIVE GAMMA LACTAMS
    KYUNG JUNG; Fiscal Year: 2005
    ..Our synthetic targets encompass lactacystin, pramanicin, statine, rolipram, epolactaene, and kainic acid...
  64. MICROVESSEL PERMEABILITY AND TUMOR METASTASIS
    Bingmei Fu; Fiscal Year: 2000
    ..In specific aim 3, the effect of 8 bromo-cAMP and agents that increase cAMP such as forskolin or rolipram on VEGF induces hyperpermeability will be examined...
  65. STRUCTURE AND FUNCTION OF NUCLEOTIDE PHOSPHODIESTERASES
    Ronald Davis; Fiscal Year: 1991
    ..the biochemical properties of the enzymes and to determine whether they are inhibited by the antidepressant rolipram, like the existing representatives. The cDNA clones, in turn, will be used to isolate genomic clones for the gene...
  66. STRUCTURE AND FUNCTION OF NUCLEOTIDE PHOSPHODIESTERASES
    Ronald Davis; Fiscal Year: 1992
    ..the biochemical properties of the enzymes and to determine whether they are inhibited by the antidepressant rolipram, like the existing representatives. The cDNA clones, in turn, will be used to isolate genomic clones for the gene...
  67. Pathology and Biology of Neurodegenerative Disease
    Michael Shelanski; Fiscal Year: 2007
    DESCRIPTION (provided by applicant): The demonstration that the drugs rolipram and forskalin reverse the inhibition of LTP induced by alpha beta in hippocampal slices and that exposure of cultured hippocampal neurons to alpha beta causes ..
  68. Pathology and Biology of Neurodegenerative Disease
    Michael Shelanski; Fiscal Year: 2005
    The demonstration that the drugs rolipram and forskalin reverse the inhibition of LTP induced by alpha beta in hippocampal slices and that exposure of cultured hippocampal neurons to alpha beta causes changes in expression of genes ..
  69. Pathology and Biology of Neurodegenerative Disease
    Michael Shelanski; Fiscal Year: 2004
    The demonstration that the drugs rolipram and forskalin reverse the inhibition of LTP induced by alpha beta in hippocampal slices and that exposure of cultured hippocampal neurons to alpha beta causes changes in expression of genes ..
  70. Pathology and Biology of Neurodegenerative Disease
    Michael Shelanski; Fiscal Year: 2006
    DESCRIPTION (provided by applicant): The demonstration that the drugs rolipram and forskalin reverse the inhibition of LTP induced by alpha beta in hippocampal slices and that exposure of cultured hippocampal neurons to alpha beta causes ..
  71. Axon Regenration: Synergistic Actions of the MAPK and Cyclic AMP Pathways
    Damien Pearse; Fiscal Year: 2009
    ..a one-time injection of cAMP into the cord above and below the implant, and a two-week subcutaneous infusion of Rolipram induced substantial growth of serotonergic fibers into the implant and beyond into the cord caudal to the implant...